top of page
Search
  • kyun09
    • Sep 24, 2022
    • 1 min read

Awarded 2022 NIH/NCI R01 Grant

Humbled and thrilled to receive our NIH/NCI R01 grant!

It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care.

Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology

Recent Posts

See All

San Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded

At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technolog

bottom of page